The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
TandemAI merges with Perpetual Medicines to enhance drug discovery capabilities.
Jul 18, 2025•11 months ago
Contract Type
partnership
New YorkBiotechnologyArtificial Intelligence
Description
TandemAI has announced a merger with Perpetual Medicines, forming a new company that will expand methods and workflows for drug discovery. The merged entity will leverage Perpetual's computational platform to accelerate peptide drug discovery with partners.
Company Information
Company
TandemAI
Location
New York, New York, United States
About
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution. TandemAI has built its networked platform from the ground up in the U.S. and China to increase the speed of drug discovery and deliver cost-effective opportunities to its partners and to the global scientific community.
New YorkBiotechnologyArtificial Intelligence